Mon, December 16, 2019

Charles Duncan Maintained (AXSM) at Buy with Increased Target to $104 on, Dec 16th, 2019

  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. th-increased-target-to-104-on-dec-16th-2019.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication
Charles Duncan of Cantor Fitzgerald, Maintained "Axsome Therapeutics, Inc." (AXSM) at Buy with Increased Target from $55 to $104 on, Dec 16th, 2019.

Charles, nor any peers, have made any analyst calls on AXSM in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30